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ABSTRACT
 
Objectives:
 
It has long been suggested that, whereas the
results of clinical studies of pharmaceuticals are general-
izable from one jurisdiction to another, the results of eco-
nomic evaluations are location dependent. There has
been, however, little study of the causes of variation,
whether differences in study results among countries are
systematic, or whether they are important for decision
making.
Methods: A literature search was conducted to identify
economic evaluations of pharmaceuticals conducted in
two or more European countries. The studies identiﬁed
were then classiﬁed by methodological type and analyzed
to assess their level of variability and to identify the main
causes of variation. Assessments were also made of the
extent to which differences in study results among coun-
tries were systematic and whether they would lead to a
different decision, assuming a range of values of the
threshold willingness-to-pay for a life-year or quality-
adjusted life-year (QALY).
Results: In total 46 intercountry drug comparisons were
identiﬁed, 29 in multicountry studies and 17 in compara-
ble single country studies that were considered to be suf-
ﬁciently similar in terms of methodology. The type of
study (i.e., trial-based or modeling study) had some
impact on variability, but the most important factor was
the extent of variation across countries in effectiveness,
resource use or unit costs, allowed by the researcher’s
chosen methodology. There were few systematic differ-
ences in study results among countries, so a decision
maker in country B, on seeing a recent economic evalua-
tion of a new drug in country A, would have little basis
on which to predict whether the drug, if evaluated, would
be more or less cost-effective in his or her country. Given
the extent of variation in cost-effectiveness estimates
among countries, the importance of this for decision
making depends on decision makers’ thresholds in
willingness-to-pay for a QALY or life-year. If a cost-
effectiveness threshold (i.e., willingness-to-pay) for a life-
year or QALY of $50,000 were assumed, the same
conclusion regarding cost-effectiveness would be reached
in most cases.
Conclusion: This review shows that cost-effectiveness
results for pharmaceuticals vary from country to country
in Western Europe and that these variations are not sys-
tematic. In addition, constraints imposed by analysts may
reduce apparent variability in the estimates. The lessons
for inferring generalizability are not straightforward,
although the implications of variation for decision mak-
ing depend critically on the cost-effectiveness thresholds
applying in Western Europe.
Keywords: costs and cost analysis, economics, Europe,
pharmaceutical.
 
Introduction
 
It has long been suggested that, whereas the results
of clinical studies of pharmaceuticals are generaliz-
able from one jurisdiction to another, the results of
economic evaluations are location dependent [1].
Recently, Drummond and Pang [2] have outlined
the factors, varying from place to place, that may
limit the generalizability of studies. These include
differences in demography and the epidemiology of
disease, differences in clinical practice patterns, and
differences in relative prices.
The potential cross-country variability in cost-
effectiveness results is a concern both for decision-
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makers and those conducting economic studies.
Decision-makers may wonder whether data from
an economic evaluation conducted elsewhere will
apply in their setting. Pharmaceutical manufactur-
ers, or other sponsors of studies, may wonder
whether a given study needs to be repeated in every
setting, with the obvious additional costs. Further-
more, if there were ever to be harmonized arrange-
ments for the pricing and reimbursement of
pharmaceuticals within the European Union (EU),
these would imply some consistency in cost-
effectiveness results across countries.
This study explores the issues surrounding vari-
ability of economic evaluations of pharmaceuticals
in Western Europe and provides answers to the fol-
lowing questions:
1. What are the major causes of variation in study
results from place to place?
2. Does the extent of variation differ among dif-
ferent health economic study types (e.g., mod-
eling studies, trial-based studies)?
3. Are there systematic differences in study results
between particular countries?
4. Is the extent of variation in study results
between countries important for decision
making?
 
Methods
 
Literature Search
 
The literature search covered the period January
1988 to December 2001. The ﬁrst phase concen-
trated on economic evaluations of pharmaceuticals
conducted in two or more European countries.
These studies, designated multicountry studies in
this article, were considered to be the best source of
evidence on variation in cost-effectiveness results
between countries, because they employ the same
study methodology across all countries and seek to
compare and contrast results by country.
Therefore, the two main databases of economic
evaluations, OHE-HEED [3] and NHS EED [4],
were searched to identify any studies of pharmaceu-
ticals that had been undertaken in more than one
European country. Copies of the full articles were
obtained for the full economic evaluations that were
found (i.e., studies that compare alternative treat-
ments in terms of costs, or costs and beneﬁts). The
second phase of the literature search was much
broader, with a view to matching studies of the
same drug in different European countries. In this
phase only OHE-HEED was used, because it has the
ability to search by drug name. The database was
searched individually for each EU country, plus
Norway and Switzerland, using the key word
PHARMACEUTICAL. Because it was expected
that the United Kingdom would have the most stud-
ies, the UK was excluded from the ﬁrst phase of the
search. Then, in the second phase, when the full list
of drug studies in the other European countries
was known, PHARMACEUTICAL 
 
+
 
 NAME OF
DRUG 
 
+
 
 UK was entered.
The abstracts were then screened to identify
full economic evaluations. These included cost-
consequences and cost-minimization studies, but
excluded cost studies of single treatments, cost of
illness studies, and methodological articles.
The abstracts of the full economic evaluations
were then screened in more detail in order to assess
the methodological comparability of studies of the
same drug in more than one country. The logic was
that a high degree of methodological comparability
would be required in order to assess variability
across countries; namely, it would be important to
be sure that differences in cost-effectiveness results
related to intercountry differences rather than dif-
ferences in methodological approach.
Of the evaluations screened, several appeared
to be multicountry studies that were not identi-
ﬁed in the initial literature search. When review
articles and papers considering drugs in different
indications were excluded, however, only a few
were deemed potentially relevant. The full arti-
cles for these were obtained and considered in
detail.
The remaining abstracts were screened (by MB).
As in the case of the multicountry studies, many
articles were excluded because they were review
articles or compared drugs in different indications.
The most methodologically homogeneous studies
were those that compared the same drug, in the
same disease, with the same comparator, using the
same, or similar, methodology (e.g., trial-based or
modeling study), with the same outcome ratio (e.g.,
cost per life-year gained, cost per QALY gained). It
was decided to concentrate on these, because any
variation seen across countries would be more likely
to represent real variation, rather than differences in
study methodology. These are referred to as single
country studies later in this article.
In assessing the homogeneity of the single coun-
try studies, consideration was given to whether the
patient populations studied were similar in the var-
ious countries. Therefore, for example, if a high-risk
patient population was studied in Germany, but a
low-risk patient population was studied in France,
this comparison would be excluded.
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In practice this potential source of variability was
not very important in trial-based studies, because all
these used the same data set. The potential for such
variation is greater in modeling studies, but in prac-
tice the drugs being studied were indicated for the
same, or similar, patient populations in all coun-
tries. Nevertheless, it is still possible that some var-
iation could be introduced through the data used to
populate the model in the various countries. For
example, the cost data used could relate to slightly
different patient populations in different countries
because of limitations in data availability.
 
Review and Classiﬁcation of Studies
 
The multicountry studies and single country studies
were then reviewed in more detail: 1) to conﬁrm
that they met the criteria for inclusion; 2) to capture
reported results on costs, outcomes, and ICERs; and
3) to identify their main methodological features.
The last point was considered important because
different degrees of variability might result from dif-
ferent study types (e.g., modeling studies, trial-
based studies). It was not possible to devise a
detailed classiﬁcation of study methods, as the level
of detail in reporting varied so much from study to
study. It was possible, however, to classify studies
into four broad types.
 
Study classiﬁcations.
 
These were:
1. Type C: Comparisons based on same effective-
ness data and resource use for all countries,
with different unit costs.
2. Type RC: Comparisons based on same effec-
tiveness data for all countries, with different
resource use and unit costs.
3. Type REC: Comparisons based on different
effectiveness data, resource use and unit costs
for all countries.
4. Type NI: Comparisons with detailed data
reported only for one country, but with negli-
gible information given about the cost-
effectiveness ratios for other countries (i.e.,
headline results only).
 
Currency conversions.
 
In multicountry studies
costs were usually reported in US$ without purchas-
ing power parity (PPP) adjustment, although in a
minority of articles conversions were made using
PPPs. The ﬁgures reported in the articles were con-
verted back to the original currencies of the coun-
tries included in the study by using the exchange
rates (to US$ or other index currency) reported in
the articless. Where the exchange rate was not
reported, the average exchange rate, for the relevant
price year to the index currency from each national
currency, was used. The data in the national curren-
cies were then converted to US$ using general PPPs
for the relevant year from the OECD database [5].
If the price year for currency conversions was not
given in the published article it was assumed that
this was 1 year before the year of publication of the
study.
In the case of the single country studies, currency
conversions were usually required, as these reported
results in different local currencies, perhaps also for
different years. In these situations the conversion
was made using the general PPP for the most appro-
priate year. Where the studies reported results for
different years, the mid-year PPP was used. All
results are reported in US$.
 
Synthesis of Results
 
To answer the four questions posed in the Introduc-
tion, the results were synthesized in the following
ways.
 
Major causes of variation in study.
 
Based on the
information in the detailed data extraction, a sum-
mary table was constructed indicating, for each
study, the main reason for the variation in study
results between countries and the inﬂuence of the
study drug cost. (The “study drug” was the phar-
maceutical product that was the main topic of the
published study.)
 
Extent of variation.
 
In addition, an assessment was
made, for each drug comparison, of the level of var-
iability in study results. Such assessments are inev-
itably judgmental. The criteria used here were as
follows:
1. The similarity in the ﬁnal incremental cost-
effectiveness ratios (ICERs) (i.e., less than two-
fold difference) among countries.
2. The percentage of countries in each study with
similar ICERs, or cost-savings.
3. The likelihood that a difference in the ICERs,
or cost-savings, would lead to a change in the
decision on the cost-effectiveness of the main
drug. For example, it would be incorrect to give
the same importance to a twofold difference
between $1000 per QALY and $2000 per
QALY, and a difference between $30,000 per
QALY and $60,000 per QALY.
On the basis of these criteria the following levels
of variability were identiﬁed:
1. Level 1: Studies where all countries presented
similar ICERs (i.e., less than twofold difference)
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or where the study drug was cost-saving for all
countries.
2. Level 2: Studies where the ratio of ICERs, or
cost-savings, among countries was greater than
twofold, but this difference was not likely to
change the decision concerning the cost-
effectiveness of the study drug; or studies where
differences in ICERs, or cost-savings, greater
than twofold occur in less than 50% of coun-
tries in a given comparison. This category also
includes studies where the study drug was dom-
inant over the alternatives in one country (or
countries) and also had a low ICER in other
countries.
3. Level 3: Studies where the ratio of ICERs, or
cost-savings, among countries was greater than
twofold, and where this difference may change
the decision concerning the cost-effectiveness of
the study drug; or studies where differences in
ICERs, or cost-savings, greater than twofold
occurred in more than 50% of countries. This
category also included studies where the study
drug was dominant in one country (or coun-
tries), yet might not be cost-effective in other
countries.
4. Level 4: Studies where there were high differ-
ences in ICERs in all, or almost all, countries
and where this difference was likely to lead to
changes in the ﬁnal decision.
In the analyses reported below, we refer to Levels
1 and 2 as representing 
 
low variability
 
 and Levels 3
and 4 as representing 
 
high variability
 
. 
 
As
 
 mentioned
above, any criteria for assessing variability are inev-
itably judgmental. All one can do is to be explicit
about the criteria used. The ultimate judge of
whether the observed variations are important
enough to limit generalizability is the decision
maker or study user. For this reason, we explored
the  relationship  between  study  results  (i.e.,  Is  the
net beneﬁt positive?) and the threshold cost-
effectiveness ratio. In essence, this represents a
sensitivity analysis of the likely importance of vari-
ability in relation to the criterion used (see System-
atic Differences in Results Between Countries).
The assessments of variability were based on the
researchers’ point estimates, or “best guess” esti-
mates, of cost-effectiveness. Ideally, the assessments
should also take into account the uncertainty in the
cost-effectiveness estimates reported. The ability to
do this, however, was limited by the relative lack of
exploration of uncertainty in the studies themselves.
Of the studies reviewed, 26% presented only point
estimates, 59% undertook one-way or multiway
sensitivity analyses, 12% presented conﬁdence
intervals based on patient-level data, and 3%
undertook a probabilistic sensitivity analysis. In
many cases, however, it was difﬁcult to validate the
methods used. Therefore, where wide ranges in
cost-effectiveness ratios were presented, the conclu-
sion would have to be that the vast majority of stud-
ies produced results that did not differ by country; a
conclusion that could be erroneous, given the
doubts about the methods used.
 
Systematic differences in results between countries.
 
A matrix table was constructed for the ﬁve major
European countries (France, Germany, Italy, Spain,
and the UK), showing the percentage of times the
study drug was more cost-effective in one country
rather than another. The objective was to ascertain
whether there were any clear patterns (i.e., Were the
results for the study drug in country A always more
cost-effective than those for country B?) or whether
it was a pure judgment call (i.e., the results for the
study drug in country A were more cost-effective
than those for country B around 50% of the time).
This table included all the drug comparisons,
whether these expressed results in terms of domi-
nance, cost savings, or incremental cost-effective-
ness ratios. In principle, a larger matrix could have
been constructed including more countries, but the
number of comparisons among countries other than
the ﬁve major countries was limited.
 
Importance of differences for decision-making.
 
Although the cost-effectiveness results for the study
drug may vary from one country to another, this
may not matter unless the incremental cost-effec-
tiveness ratio crosses a particular threshold. Such
thresholds of cost-effectiveness have been discussed
both in terms of cost per life-year gained and cost
per QALY gained [6].
Therefore, as mentioned above, the results for all
studies with a beneﬁt measure in life-years gained or
QALYs were converted to net beneﬁt by using a
lambda value (i.e., willingness-to-pay) for a QALY,
or life-year, of $50,000. This approach offered the
potential to consider a wide range of studies using
the same metric (i.e., net beneﬁt), including studies
with a positive incremental cost-effectiveness ratio,
studies indicating dominance, and studies express-
ing results in terms of net savings or net costs.
 
Results
 
Quantity of Studies and Range of Coverage
 
It was clear from the literature search that a surpris-
ing number of drugs had been studied in more than
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one country. In total, 2368 references were identi-
ﬁed. When these were screened in detail, 46 com-
parisons of drugs in more than one country were
considered to be homogeneous in respect of study
methodology (29 comparisons in multicountry
studies and 17 comparisons in single country stud-
ies). (The references to all the included studies are
given in Appendix 1.)
The range of countries included in the studies is
shown in Figure 1. As one might expect, the ﬁve
largest European countries appear in the highest
number of studies, with the UK being highest,
appearing in 67% of the 46 drug comparisons. In
part this reﬂects the English-language bias in stud-
ies appearing in OHE-HEED and NHS EED.
Indeed it should be recognized that this study is
reliant on the literature search strategies employed
by these two databases. The search strategies for
the two databases, however,  are very comprehen-
sive [3,4]. More than half the comparisons involve
only two or three countries, and the maximum
number of countries compared in any comparison
is 12.
 
Major Causes of Variation in Study Results 
from Place to Place
 
Table 1 summarizes the main reasons for variation
among the countries featured in the 46 drug com-
parisons analysed. A fuller description and catego-
rization of the studies, including an assessment of
variability according to the chosen criteria, is avail-
able from the authors.
Considering ﬁrst the type C comparisons, it
should be remembered that clinical and resource
data are common to all countries, so the only vari-
ation possible is in the unit cost (price) estimates
across countries. In total there were 19 comparisons
of this type, 13 in multicountry studies and 6 in sin-
gle country studies. There was a fairly even split
between, on the one hand, differences in the cost of
the study drug being the main reason for variation
(six cases) and, on the other hand, differences in the
cost of other resources (e.g., hospitalizations) being
important. In seven cases the results among coun-
tries were similar.
There were eight type RC comparisons, six com-
parisons in multicountry studies and two compari-
sons in single country studies. In four cases
differences in resource use was the main reason for
variation and in two cases results were fairly similar
across countries.
In type REC comparisons, of which there were
17, all three factors (effectiveness, resource use, and
unit costs) are allowed to vary. In the main, differ-
ences in resource use or cost were the main causes of
variation, although in three studies the assumed dif-
ferences in efﬁcacy or effectiveness were an impor-
tant factor. In three cases the results were fairly
similar across countries. Among the various eco-
nomic variables (e.g., study drug cost, patterns of
resource use, and unit costs of resources) it was not
possible to discern any particular trends. For the
 
Figure 1
 
Countries included in the articles analyzed.
31
23 22 22
16
12 12 11
21
0
5
10
15
20
25
30
35
UK FRA ITA GER SPA SWE NET BE Others
(11)
N
um
be
r o
f s
tu
di
es
 
Table 1
 
Main reasons for variation among countries
 
Type C (n 
 
=
 
 19) Type RC (n 
 
=
 
 8)
 
Type REC (n 
 
=
 
 17)
Clinical data
 
Not applicable Not applicable
 
3 (18%)
Total costs (including resource use and unit costs)
 
Not applicable See below
 
8 (46%)
Both clinical data and total costs
 
Not applicable See below
 
3 (18%)
Resource use
 
Not applicable 4 (50%)
 
Not clear
Drug costs and other unit costs
 
See below 1 (12.5%)
 
Not clear
Both resource use and unit costs
 
Not applicable 1 (12.5%)
 
Not clear
Drug costs
 
6 (32%) Not clear
 
Not clear
Other unit costs
 
6 (32%) Not clear
 
Not clear
Similar results
 
7 (36%) 2 (25%)
 
3 (18%)
 
Type C, comparisons based on same effectiveness data and resource use for all countries, with different unit costs.
Type RC, comparisons based on same effectiveness data for all countries, with different resource use and unit costs.
Type REC, comparisons based on different effectiveness data, resource use and unit costs for all countries.
Type NI, comparisons were excluded because of  lack of  information. These were comparisons with detailed data reported only for one country, but with negligible infor-
mation given about the cost-effectiveness ratios for other countries.
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two type NI comparisons, there was not enough
information to form any conclusions.
 
Extent of  Variability among Different Health Economic 
Study Types
 
Figure 2 shows the level of variability in study
results by type of methodology. In the case of trial-
based studies, the extent of variability depends crit-
ically on whether resource use is allowed to vary
across countries. Overall, the proportion of mode-
ling studies with results of low variability is greater
than for trial-based studies. In total, 27 out of 44
drug comparisons were classed as having results of
low variability. This analysis excludes the two type
NI comparisons.
Figure 3 shows the variability by type of compar-
ison. Here, it can be seen that REC studies have
higher variability than others. This is to be
expected, because in these studies the analyst is
placing the fewest constraints on variability. Also, it
can be seen that the extent of variability is lower for
multicountry studies than single country studies.
This may be because, in a multicountry study, the
analysts give more active consideration to the har-
monization of data and analyses.
 
Systematic Differences in Study Results 
between Countries
 
The matrix table of the relative comparisons of
cost-effectiveness among the ﬁve major countries is
shown as Table 2. There are some discernible pat-
terns. For example, the two northern European
countries with higher price levels (Germany and the
UK) tend to show results for the study drug that are
less cost-effective than the three southern countries.
Also, France seems to have results that are usually
more cost-effective than all countries, with the pos-
sible exception of Spain.
In general, however, the table shows that there is
a considerable variation in whether the result for
one country is likely to be more cost-effective than
another. Considering the 10 possible comparisons
among the countries (i.e., half the cells in the
 
Figure 2
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studies; M/NV, modeling with resource use not allowed to vary; M/V,
modeling with resource use allowed to vary; RN, total studies with
resource use not allowed to vary; RV, total studies with resource use
allowed to vary; T, total; TB, total trial-based studies; TB/NV, trial-
based studies with resource use not allowed to vary; TB/V, trial-based
studies with resource use allowed to vary.
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Figure 3
 
Variability by type of  study.
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Table 2
 
Relative comparison of  cost-effectiveness among countries
 
France more 
CE than
Germany more 
CE than
Italy more 
CE than
Spain more 
CE than
UK more  
CE than Total
France less CE than
 
– 2 (20%) 2 (22%) 4 (45%) 0 (0%) 8 (22%)
 
Germany less CE than
 
8 (80%) – 6 (55%) 6 (75%) 4 (40%)
 
24 (61%)
Italy less CE than
 
7 (78%) 5 (45%) – 3 (60%) 4 (36%)
 
19 (55%)
Spain less CE than
 
5 (55%) 2 (25%) 2 (40%) – 3 (50%)
 
12 (43%)
UK less CE than
 
8 (100%) 6 (60%) 7 (64%) 3 (50%) –
 
24 (68%)
Total
 
28 (78%) 15 (39%) 17 (45%) 16 (57%) 11 (32%)
 
Figures in each cell are number of  studies involving comparisons between respective pairs of  countries in which cost-effectiveness is less for country named in row than
country in column, or for which cost-effectiveness is greater for country named in column than country in row. Values in parentheses are percentages of  total number
of  studies for which comparisons were made for respective pairs of  countries.
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matrix), in 5 cases the percentage hovers around the
50% mark (i.e., is between 40% and 60%). This
suggests that it is often a judgment call whether a
study in country A is likely to generate results that
are more cost-effective than those in country B.
The other caution to place on Table 2 is that,
even among the ﬁve major countries, the number of
comparisons is small. It ranged from 11 (UK/Italy,
Germany/Italy) to 5 (Spain/Italy).
 
Importance of   Variation in Study Results for 
Decision-Making
 
By converting the ICERs to net beneﬁt, using a
value of $50,000 for a life-year or a QALY, a wider
range of studies can be compared using the same
metric (i.e., net beneﬁt greater than zero, or net sav-
ings). The results of this analysis are shown in
Tables 3 and 4. It can be seen that, with this implied
value of a life-year or QALY, a different decision
would be reached on only three occasions. That is,
in these cases the results for one or more countries
show a positive net beneﬁt, whereas those other
countries show a net beneﬁt less than zero. They
are: simvastatin in the case of single country studies
(Table 3); interferon beta (Table 3); and methotrex-
ate (Table 4).
Even in these three cases the quantitative differ-
ences in study results are not very large, except for
the comparison concerning beta interferon, where it
could be the case that widely different assumptions
were made in the models used. This suggests that, in
the case of single country studies, even subtle dif-
ferences in study methodology can lead to large var-
iations in cost-effectiveness estimates.
Of course, the willingness-to-pay threshold
($50,000) for a life-year or QALY was chosen arbi-
trarily and there is no reason to suppose that the
same threshold applies in all countries. Indeed, the
same threshold may not even apply to different
therapies within the same country, as other factors,
such as overall budgetary impact, may be impor-
tant. Therefore, Figure 4 shows the relationship
between the willingness-to-pay (lambda) and the
percentage of countries (averaged across studies) for
which the study drug is cost-effective.
As expected, the implications for decision
making are sensitive to lambda. For example, if the
willingness-to-pay for QALY or life-year is only
$10,000, the study drug is only found to be cost-
effective, on average, in 60% of countries included
in the drug comparisons. If the willingness-to-pay is
$50,000, however, the study drug is found to be
cost-effective in, on average, 85% of countries
included in the drug comparisons. There are few
public statements about the willingness-to-pay
threshold applying in different countries, although
most statements imply thresholds between $10,000
and $50,000. Thus, the extent to which variation in
study results may be considered to be important
clearly depends on precisely where, in this range,
countries’ willingness-to-pay thresholds fall.
 
Discussion
 
There is a surprisingly large number of studies
examining the cost-effectiveness of pharmaceuticals
in more than one European country. The literature
review identiﬁed almost 2400 references, and 46
intercountry comparisons of pharmaceuticals, hav-
ing a high degree of methodological comparability,
were found.
In considering the factors causing variation
between countries, it was noted that not all studies
allowed all factors to vary. For example, many stud-
ies used, or assumed, the same effectiveness data
across countries and many the same resource use
data. The main causes of variations appeared to be
differences in the major cost drivers, such as hospi-
talization costs and study drug cost. There was also
some evidence that where the analyst allowed fac-
tors to vary by country (i.e., in trial-based studies
where resource use varies by country), study results
tended to be more variable. Therefore, to a large
extent the amount of variation in study results
across countries was conditioned by the amount
that the analysts allowed. The key factor affecting
the variation of results from country to country
appears to be whether resource use is allowed to
vary across countries, in particular, for trial-based
studies. Therefore, analysts should provide strong
arguments for pooling resource use data [7]. Oth-
erwise, it should be allowed to vary.
 
Figure 4
 
Percentage of  countries in which drug is cost-effective
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Table 4
 
Level of  variation among countries using net beneﬁts (studies without ICERs)
 
Main drug Comparator
 
Type of  
comparison
Outcome 
measure
 
Net cost
 
Net beneﬁt 
from $0
to $10,000
$10,000
to 
$20,000
$20,000
to 
$30,000
$30,000
to 
$40,000
$40,000
to 
$50,000
Greater  
than 
$50,000
 
Multicountry cost-minimization studies
 
Gemcitabine Cisplatin/Itoposide C
 
Cost-
difference
GE ($659)
SP ($1392)
 
Single country cost-minimization studies
 
Methotrexate
 
Laparoscopic 
salpingectomy
 
REC
 
Cost-
difference
 
NE (–$1469) FR ($779)
 
Multicountry “cost-savings” studies
 
rhDNase Placebo C Net savings
 
UK ($660)
IT ($864)
GE ($934)
FR ($1070)
 
Neoral Sandimmune C Net savings
 
BE ($1615)
UK ($2388)
FR ($3254)
 
Lenograstim Placebo C Net savings
 
GE ($131)
IT ($207)
 
Eptiﬁbatide Placebo C Net savings SP (–$568)
IT (–$397)
UK (–$360)
GE (–$347)
FR (–$251)
NE (–$138)
Meloxicam Diclofenac RC Net savings IT ($2-$12)
UK ($7-$24)
FR ($4-$45)
Misoprostol No Misoprostol RC Net savings FR
(–$15 to $79)
UK
(–$3 to –$72)
BE 
(–$5 to –$63)
Abbreviation: ICERs, incremental cost-effectiveness ratios.
Nevertheless, it should be recognized that allow-
ing resource use to vary is a double-edged sword
when there is not enough statistical power to iden-
tify meaningful variation in resource use across
countries. Variation in resource use can be a com-
bination of true differences, which usually imply
less generalizability of CE results, and sampling var-
iation, which should not be allowed to affect infer-
ences about generalizability. When these sources of
variation cannot be distinguished, dampening all
variation by pooling resource data can seemingly,
but falsely, increase the appearance of generalizabil-
ity, whereas allowing all variation has the opposite
effect. In such cases, choices about pooling resource
use may need to be driven by broader arguments
about known similarities or dissimilarities in treat-
ment patterns or health-care systems.
The role of the study drug cost, along with its
impact on the variation of study results across coun-
tries, is quite complex. In cases where a multina-
tional economic evaluation is being conducted
before the launch of a new product, the manufac-
turer would have the option to choose a price that
would result in the drug being cost-effective in a
wide range of countries.
On the other hand, some studies may be con-
ducted after the drug price has been set, either by
the manufacturer or the authorities. Indeed, in a
number of countries in Europe prices are highly reg-
ulated, often by comparison with prices in other
countries. In these situations one might see harmo-
nization of drug prices, but not necessarily harmo-
nization of cost-effectiveness results.
Also, it should be recognized that the drug prices
used in the published study may not necessarily be
those applying in practice. This could be because
manufacturers offer discounts or because the eco-
nomic study was undertaken before price negotia-
tions, during which price reductions may be
enforced.
There were few systematic differences in cost-
effectiveness among the ﬁve major European coun-
tries, although there was a slight trend for the
results for the drugs studied in France, Italy, and
Spain to be more cost-effective than those for the
same drugs in Germany and the UK. The potential
reasons why incremental ratios are higher in coun-
tries with higher price levels are many and complex.
On the one hand one could argue that this is to be
expected. Namely, in a more expensive country
Barbieri et al.20
decision-makers might be willing to bear a higher
incremental cost-effectiveness ratio. On the other
hand it may suggest that the price of the study drug
is not being set at a common European price.
Otherwise one might expect the drug to be more
cost-effective in a more expensive country, as the
cost-offsets are likely to be greater. This issue merits
further exploration.
The pattern of cost-effectiveness among coun-
tries, however, was generally not stable enough for
decision-makers to infer that if a given drug was
found to be cost-effective in country A, it would
almost always be more cost-effective in country B.
This suggests that decision-makers would be unwise
to take cost effectiveness results from elsewhere and
assume that they apply in their own setting. Never-
theless, although there was considerable variation
in cost-effectiveness results across countries, the
implications for decision-making were more similar.
That is, if decision makers adopted a threshold,
of willingness-to-pay for a life-year or QALY, of
$50,000, they would almost always make the same
decision to adopt or reject a new drug for reim-
bursement in all countries.
There is no reason, however, to suppose that the
threshold of $50,000 per QALY, or life-year, gained
is the most relevant, or that the threshold is the
same for all countries. Our analysis shows that the
percentage of countries experiencing a cost-effective
result in a given study is very dependent on the cho-
sen threshold. This is an important ﬁnding, given
that it has previously been suggested that variations
across Europe in the willingness-to-pay for new
healthy technologies is probably the greatest barrier
to a common European drug pricing and reimburse-
ment policy [8].
The ways in which methodological decisions
taken by analysts affect variability merits further
investigation. For example, it would be interesting
to explore whether planning and executing a study
in multiple countries at the same time (i.e., in a mul-
ticountry study) encourages the kind of methodo-
logical homogeneity that results in less variability in
ﬁndings, or enables the analysts to anticipate, and
better confront, issues relating to generalizability.
The limitations of this study should be noted.
First, the databases for the literature search contain
excellent detail about health economic studies, but
are more representative of studies that are both
published and written in the English language. Any
relation between these conditions and the variabil-
ity in studies may be reﬂected in our results. Second,
by using the published literature as a starting point,
the study is constrained by the reporting of results
in the articles analyzed, in particular the ways in
which the uncertainty in cost-effectiveness estimates
is explored. Clearly, it would be much better to have
access to the patient-level data or the models used.
Third, characterizations about the levels and
sources of variation are based on the best judgments
of the authors within the bounds described, but may
have been judged differently by other researchers.
Finally, our analysis of relevance to decision making
could only focus on high-level decisions, such as
country-level reimbursement, where some thresh-
olds of willingness-to-pay have been discussed. Var-
iations in cost-effectiveness results also exist within
countries and local criteria may also affect deci-
sions, such as the degree of utilization of particular
drugs. This is, however, beyond the scope of our
analysis. Finally, it is possible that complex interac-
tions exist between prices, resources, and effective-
ness in different countries (settings) [9]. Only the
REC studies even begin to tackle this issue and a
thorough exploration would require access to
patient-level data.
Despite these limitations, however, this study
represents the most comprehensive analysis to date
of the variation in the results of cost-effectiveness
studies, of drugs, in Europe. It should greatly con-
tribute to the debate about the sources of variation
in economic evaluations, and the signiﬁcance of
these for drug reimbursement decisions.
Conclusions
The result shows that there is variability in cost-
effectiveness estimates for pharmaceuticals in West-
ern Europe. The main sources of variability depend
on study type and the extent of variability depends
critically on analytic decisions made by the
researcher, such as whether or not to use a pooled
estimate of resource use for all countries in the study.
The lessons for inferring generalizability are not
straightforward and whether the results of a given
study are generalizable is ultimately a judgment
made by the study user. Nevertheless, this research
shows that the differences in cost-effectiveness
results between countries are not systematic, which
makes inferences from one country to another dif-
ﬁcult. Also, the implications of variation for decision
making depend critically on the cost-effectiveness
thresholds applying in Western Europe.
We are grateful to members of the group and three anon-
ymous referees for constructive comments. The contract
for the study gave permission for publication of the
results.
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